China Veterinary Medicine Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

China Veterinary Medicine Market Size

• The China veterinary medicine market size was valued at USD 21.89 billion in 2024 and is expected to reach USD 41.18 billion by 2032, at a CAGR of 8.22% during the forecast period
• The market growth is largely fueled by the growing demand for animal healthcare, increasing livestock production, and the rising prevalence of zoonotic and chronic animal diseases across China, leading to heightened usage of veterinary pharmaceuticals and biologics in both livestock and companion animals
• Furthermore, rising consumer awareness regarding pet health, growing pet ownership, and supportive government initiatives in animal vaccination and food safety are establishing veterinary medicines as an essential component of the country’s animal health ecosystem. These converging factors are accelerating the uptake of veterinary medicine solutions, thereby significantly boosting the industry's growth

China Veterinary Medicine Market Analysis

• Veterinary medicines, comprising pharmaceuticals and biologics used for animal treatment and disease prevention, are increasingly vital components of China’s rapidly evolving animal health ecosystem due to their role in ensuring livestock productivity, food safety, and pet wellness
• The escalating demand for veterinary medicines in China is primarily fueled by the rising prevalence of zoonotic diseases, expanding livestock population, and the increasing awareness among pet owners about animal health and welfare
• China dominated the Asia-pacific veterinary medicine market with the largest revenue share of 41.7% in 2024, driven by government initiatives promoting livestock disease control, growing pet adoption in urban areas, and rising investments in veterinary research and infrastructure development
• The country’s veterinary sector is also supported by robust pharmaceutical manufacturing capabilities and a surge in demand for veterinary vaccines and antiparasitic drugs due to the increasing focus on preventing disease outbreaks in both livestock and companion animals
• The production animals segment dominated the China veterinary medicine market with a market share of 62.3% in 2024, due to the high demand for veterinary medicines in livestock sectors such as poultry, cattle, and swine farming. The segment’s growth is primarily driven by the rising consumption of meat, milk, and other animal products in China, combined with government support for animal health

Report Scope and China Veterinary Medicine Market Segmentation 

China Veterinary Medicine Market Trends

“Increasing Focus on Companion Animal Health and Preventive Care”

• A prominent trend shaping the China veterinary medicine market is the growing attention toward companion animal health, especially in urban areas where pet ownership is rising steadily. With a growing middle class and increasing disposable income, Chinese consumers are investing more in preventive veterinary care, including vaccines, nutritional supplements, and wellness check-ups for pets
• The shift from curative to preventive veterinary healthcare is driving demand for advanced pharmaceuticals, diagnostics, and treatment protocols
• In addition, the rise in pet humanization is encouraging the adoption of premium veterinary services and medications, further boosting the market
• This trend is supported by government efforts to strengthen animal disease surveillance and promote responsible pet ownership, which encourages adherence to regular veterinary care
• E-commerce platforms in China are also playing a critical role by making veterinary products more accessible to pet owners, particularly in second- and third-tier cities
• There is a growing preference for natural and organic veterinary supplements as consumers become more health-conscious about their pets
• Technological advancements, such as wearable health trackers for pets and AI-enabled veterinary diagnostics, are also gaining traction, improving early disease detection and monitoring
• Local veterinary clinics are expanding their service offerings to include wellness programs, grooming, dental care, and specialized treatments, reflecting the growing demand for holistic animal healthcare

China Veterinary Medicine Market Dynamics

Driver

“Rising Livestock Population and Demand for Animal Protein”

• China has one of the world’s largest livestock industries, particularly in swine, poultry, and cattle, creating sustained demand for veterinary drugs
• Changing dietary habits and a growing middle-class population are increasing the consumption of meat and dairy products
• Outbreaks of diseases such as African swine fever (ASF) have driven awareness about biosecurity and veterinary vaccines
• The government is investing in animal disease monitoring systems and emergency preparedness to mitigate agricultural losses
• Modernization of farms and adoption of industrial-scale animal husbandry practices increase reliance on professional veterinary services
• Foreign investments and collaborations are driving innovation in animal health products and diagnostics
• Rising demand for antibiotic alternatives like probiotics and immunity boosters due to global antimicrobial resistance concerns
• China’s Belt and Road Initiative is improving infrastructure for cold chains and veterinary supply chains in rural areas

Restraint/Challenge

“Regulatory Complexity and Counterfeit Drug Concerns”

• The market is governed by complex and evolving regulations from authorities like the Ministry of Agriculture and Rural Affairs (MARA)
• Lengthy approval processes for veterinary drug registration deter small or international players from entering the market swiftly
• The prevalence of counterfeit or substandard drugs undermines consumer trust and affects the health of animals
• Rural and underserved areas often face limited access to quality-assured veterinary medicines
• There is a shortage of licensed veterinarians, particularly in remote livestock-farming regions
• Lack of standardized distribution and tracking systems makes it difficult to ensure drug authenticity and compliance
• High costs of GMP compliance and facility upgrades challenge smaller domestic manufacturers
• Rising global scrutiny over antibiotic overuse in animals is prompting stricter regulations, which could impact market growth if not addressed properly

China Veterinary Medicine Market Scope

The market is segmented into on the basis of product, animal type, and distribution channel.

• By Product

On the basis of product, the China veterinary medicine market is segmented into biologics, pharmaceuticals, and medicated feed additives. The pharmaceuticals segment dominated the largest market revenue share of 45.6% in 2024, driven by the rising prevalence of livestock diseases, increased use of antibiotics and antiparasitics, and greater awareness of veterinary care. Pharmaceuticals are widely used for both preventive and curative treatments, especially in large-scale production animal farming.

The biologics segment is expected to witness the fastest CAGR of 9.8% from 2025 to 2032, owing to increasing investments in vaccine development, growing concerns over antimicrobial resistance, and the adoption of preventive healthcare strategies in animal husbandry. Advancements in recombinant and DNA-based vaccines further contribute to the rapid growth of this segment.

• By Animal Type

On the basis of animal type, the market is segmented into production animals, companion animals, and others. The production animals segment held the largest market share of 62.3% in 2024, due to the high demand for veterinary medicines in livestock sectors such as poultry, cattle, and swine farming. The segment’s growth is primarily driven by the rising consumption of meat, milk, and other animal products in China, combined with government support for animal health.

The companion animals segment is projected to grow at the fastest rate of 10.5% from 2025 to 2032, fueled by the rising pet ownership trend, increased spending on pet healthcare, and growing awareness about zoonotic diseases. Urbanization and changing lifestyles have significantly influenced the growth of veterinary care for pets in China.

• By Distribution Channel

On the basis of distribution channel, the China veterinary medicine market is segmented into veterinary hospitals & clinics, e-commerce, offline retail stores, and others. The veterinary hospitals & clinics segment accounted for the largest revenue share of 48.9% in 2024, driven by the increasing availability of advanced treatment facilities, professional veterinary services, and the growing preference for clinical consultations.

The e-commerce segment is expected to witness the fastest growth during the forecast period, with a CAGR of 11.3% from 2025 to 2032, owing to the convenience of online purchasing, discounts, and the availability of a wide range of veterinary products. The digital transformation in China’s retail and healthcare sectors is significantly contributing to the segment’s expansion.

China Veterinary Medicine Market Regional Analysis

• China dominated the veterinary medicine market in Asia-Pacific with the largest revenue share of 41.9% in 2024, driven by rapid urbanization
• Increasing livestock farming, and strong national support for animal healthcare and food safety initiatives
• The rising consumption of animal products such as meat, eggs, and dairy, along with escalating investments in veterinary R&D, continues to bolster the market's expansion across various provinces

China Veterinary Medicine Market Share

The China veterinary medicine industry is primarily led by well-established companies, including:

• China Animal Husbandry Industry Co. Ltd. (China)
• Boehringer Ingelheim International GmbH (Germany)
• Zoetis Services LLC (U.S.)
• Bimeda, Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Charles River Laboratories International, Inc. (U.S.)
• Eurofins Scientific (Luxembourg)
• Evotec SE (Germany)
• BioIVT (U.S.)
• Albany Molecular Research Inc. (AMRI) (U.S.)
• Elanco (U.S.)
• Ceva (France)
• Vetoquinol (France)

Latest Developments in China Veterinary Medicine Market

• In November 2023, Bimeda, Inc., an Irish animal health company, announced the opening of its state-of-the-art sterile injectable manufacturing facility in China. This facility is expected to increase the company’s portfolio for a growing consumer base in both China and the AMEA-ANZ region
• In May 2023, Kuehne+Nagel announced a partnership with Elanco, an animal healthcare company in China. The company opened a manufacturing warehouse and a distribution center for Elanco's finished goods. This partnership is expected to increase Elanco’s footprint in China’s fast-growing animal healthcare market

SKU-70830